News Release

Continued smoking after MS diagnosis associated with accelerated disease progression

Peer-Reviewed Publication

JAMA Network

Continued smoking after a diagnosis of multiple sclerosis (MS) appears to be associated with accelerated disease progression compared with those patients who quit smoking, according to an article published online by JAMA Neurology.

MS is a neurogenerative disease and smoking is one of its known risk factors. While MS begins with an initial course of irregular and worsening relapses, it usually changes after about 20 years into secondary progressive (SP) disease. The time from onset to conversion to SPMS is a frequently used measure of disease progression.

Jan Hillert, M.D., Ph.D., of the Karolinska Institutet at Karolinska University Hospital Solna, Stockholm, and coauthors studied patients in Sweden with MS who smoked at diagnosis (n=728), of whom 216 converted to SP. Among the 728 smokers, 332 were classified as "continuers" who smoked continuously from the year after diagnosis and 118 were "quitters" who stopped smoking the year after diagnosis. Data on 1,012 never smokers also were included. Nearly 60 percent of patients with MS were smokers in the present study cohort and in a Swedish cohort of new cases, according to study background.

Analysis by the authors suggests each additional year of smoking after diagnosis accelerated the time to SP conversion by 4.7 percent. Other analysis suggested that those patients who continued to smoke each year after diagnosis converted to SP faster (at age 48) than those who quit (at age 56). The authors note it is impossible to rule out other confounding factors.

"This study demonstrates that smoking after MS diagnosis has a negative impact on the progression of the disease, whereas reduced smoking may improve patient quality of life, with more years before the development of SP disease. Accordingly, evidence clearly supports advising patients with MS who smoke to quit. Health care services for patients with MS should be organized to support such a lifestyle change," the study concludes.

(JAMA Neurol. Published online September 8, 2015. doi:10.1001/jamaneurol.2015.1788. Available pre-embargo to the media at

Editor's Note: Authors made conflict of interest disclosures and detailed funding/support. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Editorial: Smoking Beyond Multiple Sclerosis Diagnosis

In a related commentary, Myla D. Goldman, M.D., of the University of Virginia, Charlottesville, and Olaf Stüve, M.D., Ph.D., of the University of Texas Southwestern Medical Center at Dallas, write: "In summary, this study adds to the important research demonstrating that smoking is an important modifiable risk factor in MS. Most importantly, it provides the first evidence, to our knowledge, that quitting smoking appears to delay onset of secondary progressive MS and provide protective benefit. Therefore, even after MS diagnosis, smoking is a risk factor worth modifying."

(JAMA Intern Med. Published online September 8, 2015. doi:10.1001/jamainternmed.2015.1805. Available pre-embargo to the media at

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures


Media Advisory: To contact corresponding author Jan Hillert, M.D., Ph.D., email To contact editorial corresponding author Myla D. Goldman, M.D., please call Josh Barney at 434-243-1988 or email

To place an electronic embedded link in your story: Links will be live at the embargo time:

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.